[Effect of cisapride on esophageal motility in healthy probands and patients with progressive systemic scleroderma].
Prokinetic agents might be useful in patients with progressive systemic sclerosis (PSS) who have disturbed function of the lower esophageal sphincter and impaired acid-clearance of the tubular esophagus. We therefore compared, by means of esophageal manometry, the effect of 20 mg cisapride orally vs. placebo in 12 patients with progressive systemic sclerosis and proven esophageal dysfunction as well as in 10 healthy volunteers in a double-blind, prospective trial. An increase of the lower esophageal resting pressure from 18.1 +/- 2.4 mm Hg to 23.9 +/- 8.1 mm Hg* after cisapride administration was observed in healthy volunteers, and from 10.9 +/- 3.2 mm Hg to 13.6 +/- 4.0 mm Hg* in the PSS patients. The amplitudes of peristaltic waves in the distal part of the esophagus were increased by cisapride from 83.8 +/- 10.6 mm Hg to 95.6 +/- 15.5 mm Hg* in volunteers and from 28.9 +/- 12.8 mm Hg to 36.8 +/- 16.2 mm Hg in patients (*:P less than 0.05). These results indicate that cisapride has a therapeutic rationale in the treatment of esophageal dysfunction in PSS; further clinical investigations are justified.
Abteilung für Gastroenterologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt/Main.
T
T
Wehrmann
W F
WF
Caspary
D000328:Adult; D020117:Cisapride; D004311:Double-Blind Method; D015154:Esophageal Motility Disorders / Q000188:drug therapy*; D004947:Esophagus / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D012702:Serotonin Antagonists
D010880:Piperidines; D012702:Serotonin Antagonists; D020117:Cisapride
Einfluss von Cisaprid auf die Oesophagusmotilität bei Gesunden und Patienten mit progressiver systemischer Sklerodermie.